Effect of lysozyme on the stability of polyester nanocapsules and nanoparticles: stabilization approaches

被引:35
作者
Calvo, P [1 ]
VilaJato, JL [1 ]
Alonso, MJ [1 ]
机构
[1] UNIV SANTIAGO DE COMPOSTELA,SCH PHARM,DEPT PHARM & PHARMACEUT TECHNOL,SANTIAGO COMPOSTE 15706,SPAIN
关键词
colloidal carriers; poly-epsilon-caprolactone; protein adsorption; enzymatic degradation;
D O I
10.1016/S0142-9612(97)00061-6
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The efficacy of colloidal particles as drug carriers is closely related to their interaction with proteins and enzymes in different body fluids. In the present work, we analysed the interaction phenomenon between lysozyme (LZM), a positively charged enzyme that is highly concentrated in mucosas, and two different drug carriers: nanocapsules made of an oily core coated by the polymer poly-epsilon-caprolactone (PECL) and nanoparticles made solely of PECL. Results showed that the interaction of LZM with these colloidal drug carriers is highly affected by their surface charge. Nanocapsules, because of their important negative charge (-40 mV), adsorbed a great amount of LZM, which is positively charged. This adsorption process, which was also evidenced by the significant reduction of the nanocapsules' negative surface charge, led to the degradation of the polymer coating and the aggregation of the nanocapsules. In contrast, nanoparticles had a low negative surface charge (-8 mV) and adsorbed only a small amount of LZM, which did not cause the destabilization of the system. Furthermore, the molecular weight of the polymer forming the nanoparticles did not change. Finally, it was observed that the destabilizing effects caused by the adsorption of LZM onto the nanocapsules can be prevented by previous adsorption of the cationic poly(amino acid) poly-L-lysine. Using this approach the adsorption of LZM was hindered and its consequences avoided. (C) 1997 Elsevier Science Limited. All rights reserved.
引用
收藏
页码:1305 / 1310
页数:6
相关论文
共 22 条
  • [1] BODY DISTRIBUTION OF FULLY BIODEGRADABLE [C-14] POLY(LACTIC ACID) NANOPARTICLES COATED WITH ALBUMIN AFTER PARENTERAL ADMINISTRATION TO RATS
    BAZILE, DV
    ROPERT, C
    HUVE, P
    VERRECCHIA, T
    MARLARD, M
    FRYDMAN, A
    VEILLARD, M
    SPENLEHAUER, G
    [J]. BIOMATERIALS, 1992, 13 (15) : 1093 - 1102
  • [2] BERGMEYER HV, 1983, METHODS ENZYMATICS A, V4
  • [3] BERGMEYER HV, 1983, METHODS ENZYMATICS A, V3
  • [4] Interaction of Serum Components with Poly(methylmethacrylate) Nanoparticles and the Resulting Body Distribution after Intravenous Injection in Rats
    Borchard, G.
    Kreuter, J.
    [J]. JOURNAL OF DRUG TARGETING, 1993, 1 (01) : 15 - 19
  • [5] BRADFIELD JWB, 1984, MICROSPHERES DRUG TH, P25
  • [6] Improved ocular bioavailability of indomethacin by novel ocular drug carriers
    Calvo, P
    Alonso, MJ
    VilaJato, JL
    Robinson, JR
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1996, 48 (11) : 1147 - 1152
  • [7] Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers
    Calvo, P
    VilaJato, JL
    Alonso, MJ
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (05) : 530 - 536
  • [8] Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A
    Calvo, P
    Sanchez, A
    Martinez, J
    Lopez, MI
    Calonge, M
    Pastor, JC
    Alonso, MJ
    [J]. PHARMACEUTICAL RESEARCH, 1996, 13 (02) : 311 - 315
  • [9] STUDY OF THE MECHANISM OF INTERACTION OF POLY(EPSILON-CAPROLACTONE) NANOCAPSULES WITH THE CORNEA BY CONFOCAL LASER-SCANNING MICROSCOPY
    CALVO, P
    THOMAS, C
    ALONSO, MJ
    VILAJATO, JL
    ROBINSON, JR
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 103 (03) : 283 - 291
  • [10] Fessi H., 1988, Patent No. [0274961, 274961,A1, 274961]